Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD
(PROSPECT Trial)
Recruiting in Palo Alto (17 mi)
+47 other locations
Age: Any Age
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Global Blood Therapeutics
No Placebo Group
Breakthrough Therapy
Trial Summary
What is the purpose of this trial?
This registry is an observational study designed to evaluate the effect of Oxbryta in individuals with SCD in a real-world setting.
Eligibility Criteria
Inclusion Criteria
Willing and able to provide written informed consent (aged ≥ 18 years), parental/ guardian consent and participant assent (aged ≥ 12 to <18 years) per local regulations, or pediatric participants (aged 4 to <12 years) with parental/guardian consent per Institutional Review Board (IRB) policy and requirements, consistent with ICH guidelines
Male or female participants with documented diagnosis of sickle cell disease (all genotypes)
Undergoing treatment with Oxbryta according to the Oxbryta USPI
Treatment Details
Interventions
- Oxbryta® (voxelotor) 500mg Tablets (Hemoglobin S Polymerization Inhibitor)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Oxbryta Product RegistryExperimental Treatment1 Intervention
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Nemours Children's HealthWilmington, DE
Stanford Children's Health- Lucille Packard Children's Hospital StanfordPalo Alto, CA
University of Maryland Medical CenterCollege Park, MD
University of Illinois at Chicago (UIC) Sickle Cell CenterChicago, IL
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Global Blood TherapeuticsLead Sponsor
PfizerLead Sponsor